Compounds > jorumycin
Page last updated: 2024-11-11

jorumycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

jorumycin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9849761
CHEMBL ID539920
MeSH IDM0494262

Synonyms (3)

Synonym
CHEMBL539920
jorumycin
[(1r,2s,10r,12s,13s)-12-hydroxy-7,18-dimethoxy-6,17,21-trimethyl-5,8,16,19-tetraoxo-11,21-diazapentacyclo[11.7.1.02,11.04,9.015,20]henicosa-4(9),6,15(20),17-tetraen-10-yl]methyl acetate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID265918Antiproliferative activity against human A549 cell line2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
Antitumor activity of tetrahydroisoquinoline analogues 3-epi-jorumycin and 3-epi-renieramycin G.
AID1871296Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 4 days by Cell counting kit-8 assay2021European journal of medicinal chemistry, Jan-15, Volume: 210Renieramycin-type alkaloids from marine-derived organisms: Synthetic chemistry, biological activity and structural modification.
AID1871295Cytotoxicity against human HT-29 cells assessed as cell growth inhibition2021European journal of medicinal chemistry, Jan-15, Volume: 210Renieramycin-type alkaloids from marine-derived organisms: Synthetic chemistry, biological activity and structural modification.
AID1871294Cytotoxicity against human Melanoma cell line assessed as cell growth inhibition2021European journal of medicinal chemistry, Jan-15, Volume: 210Renieramycin-type alkaloids from marine-derived organisms: Synthetic chemistry, biological activity and structural modification.
AID1871292Cytotoxicity against mouse NIH3T3 cells assessed as cell growth inhibition at 50 ng/ml2021European journal of medicinal chemistry, Jan-15, Volume: 210Renieramycin-type alkaloids from marine-derived organisms: Synthetic chemistry, biological activity and structural modification.
AID1871289Cytotoxicity against mouse P388 cells assessed as cell growth inhibition2021European journal of medicinal chemistry, Jan-15, Volume: 210Renieramycin-type alkaloids from marine-derived organisms: Synthetic chemistry, biological activity and structural modification.
AID265919Antiproliferative activity against human HCT116 cell line2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
Antitumor activity of tetrahydroisoquinoline analogues 3-epi-jorumycin and 3-epi-renieramycin G.
AID1871293Cytotoxicity against human A549 cells assessed as cell growth inhibition2021European journal of medicinal chemistry, Jan-15, Volume: 210Renieramycin-type alkaloids from marine-derived organisms: Synthetic chemistry, biological activity and structural modification.
AID1871297Cytotoxicity against human QG-56 cells assessed as cell growth inhibition incubated for 4 days by Cell counting kit-8 assay2021European journal of medicinal chemistry, Jan-15, Volume: 210Renieramycin-type alkaloids from marine-derived organisms: Synthetic chemistry, biological activity and structural modification.
AID427238Cytotoxicity against human HCT116 cells at 1.4 to 100 nM after 3 days by MTT assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Chemistry of renieramycins. Part 8: synthesis and cytotoxicity evaluation of renieramycin M-jorunnamycin A analogues.
AID427237Cytotoxicity against human QG56 cells at 1.4 to 100 nM after 3 days by MTT assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Chemistry of renieramycins. Part 8: synthesis and cytotoxicity evaluation of renieramycin M-jorunnamycin A analogues.
AID1871298Cytotoxicity against human DU-145 cells assessed as cell growth inhibition incubated for 4 days by Cell counting kit-8 assay2021European journal of medicinal chemistry, Jan-15, Volume: 210Renieramycin-type alkaloids from marine-derived organisms: Synthetic chemistry, biological activity and structural modification.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's2 (28.57)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.10 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		2.5320monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
tyrosine
Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.		7.0810amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
aziridine
[no description available]		7.0510azacycloalkane;
aziridines;
saturated organic heteromonocyclic parent		alkylating agent
bortezomib
[no description available]		3.4110amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
doxorubicin hydrochloride
[no description available]		3.4110anthracycline
renieramycin m
renieramycin M: from the Thai sponge Xestospongia sp.; structure in first source		8.8730
jorunnamycin a
jorunnamycin A: structure in first source		7.7830isoquinolines
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		02.0510
Carcinoma, Anaplastic
[description not available]		02.0510
Cancer of Colon
[description not available]		02.0510
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0510
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		02.0510
Colonic Neoplasms
Tumors or cancer of the COLON.		02.0510
Benign Neoplasms
[description not available]		03.2310
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.2310